BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15127232)

  • 1. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
    Takigawa N; Segawa Y; Kishino D; Fujiwara K; Tokuda Y; Seki N; Shinkai T; Watanabe Y; Hiraki S; Kozuki T; Gemba K; Tabata M; Kiura K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):230-6. PubMed ID: 15127232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
    Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
    Nugent FW; Mertens WC; Graziano S; Levitan N; Collea R; Gajra A; Marshall J; McCann J
    Lung Cancer; 2005 May; 48(2):267-73. PubMed ID: 15829328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
    Ramalingam S; Dobbs TW; Einzig AI; Wojtowicz-Praga S; Cascino M; Bonomi P; Belani CP
    Cancer Chemother Pharmacol; 2004 May; 53(5):439-44. PubMed ID: 15132135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study.
    De Petris L; Migliorino MR; Ceribelli A; Martelli O; Di Molfetta M; Mancuso A; De Santis S; Di Salvia R; De Marinis F
    Anticancer Res; 2005; 25(6C):4713-7. PubMed ID: 16334165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
    Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
    Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
    Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
    Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
    Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.
    Feliu J; Martín G; Castro J; Sundlov A; Rodriguez-Jaráiz A; Casado E; Lomas M; Madroñal C; Galán A; Belda C; Gonzalez-Barón M
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):527-31. PubMed ID: 16555090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
    Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
    J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
    Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
    Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.